The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Caroline SolasCatherine Tamalet

Abstract

To evaluate the predictive value of the genotypic inhibitory quotient (GIQ) on the atazanavir response in treatment-experienced HIV-1-infected patients. Thirty-six patients receiving an atazanavir-containing regimen were enrolled in the study. Atazanavir plasma concentrations were measured at month (M) 1, and genotype was performed at baseline. Virologic response was defined as a viral load <400 copies/mL or a decrease > or =1 log10. The median numbers (range) of previous regimens, baseline protease inhibitors, and atazanavir resistance mutations were 8 (0 to 20), 3 (0 to 15), and 1 (0 to 10), respectively. The atazanavir-GIQ was associated with virologic response at M6, with a median value (range) of 365 (50 to 1172) in responder patients compared with 126 (23 to 1126) in nonresponders (P = 0.05). The cutoff value estimated for the atazanavir-GIQ was 183 (receiver operating characteristic curve test: 60% specificity, 74% sensitivity). Virologic response was achieved in 74% of patients with an atazanavir-GIQ >183 compared with only 26% of patients with an atazanavir-GIQ <183 (P = 0.02). Neither the number of mutations nor the atazanavir trough concentration was predictive of the virologic response. In pretreated patients, the a...Continue Reading

References

Mar 5, 2004·The New England Journal of Medicine·François Clavel, Allan J Hance
Aug 26, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Mireille HenryCatherine Tamalet

❮ Previous
Next ❯

Citations

Feb 2, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark MirochnickUNKNOWN IMPAACT 1026s Study Team
Nov 14, 2012·Antimicrobial Agents and Chemotherapy·Sylvain GoutelleUNKNOWN Lyon HIV Cohort Study Group
Oct 30, 2009·Expert Opinion on Drug Metabolism & Toxicology·Danièle Bentué-FerrerEric Bellissant
Sep 4, 2009·Clinical Pharmacokinetics·Monika Schöller-GyüreRichard M W Hoetelmans
Aug 9, 2019·Therapeutic Drug Monitoring·Dario CattaneoUNKNOWN IATDMCT Anti-Infective Committee
Jun 17, 2020·Expert Review of Clinical Pharmacology·Andrea GiacomelliStefano Rusconi
Feb 2, 2012·Paediatric Drugs·Emma D Deeks
Jun 6, 2009·Drugs·Katherine F CroomSusan J Keam
Feb 8, 2011·Clinical Pharmacokinetics·Michael N Neely, Natella Y Rakhmanina

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.